A solidly profitable company with $446 million on top of $3.2 billion in revenue for the first nine months of 2012, Zoetis is poised to enjoy the largest stock market debut since Facebook's offering last spring. Zoetis raised $2.2 billion in its IPO.
The shares began trading 1 February 2013 on the NYSE under the symbol "ZTS" and were a hit among investors as shares jumped nearly 20% from their initial price of $26 to $31.01.
About Zoetis:
Formed six decades ago as the animal health business of Pfizer, Zoetis focuses on manufacturing and selling medicines for livestock and pets and is a leading animal health company, dedicated to supporting its customers and their businesses. The company generated annual revenue of $4.2 billion in fiscal 2011. Zoetis has more than 9,500 employees and a local presence in approximately 70 countries, including 29 manufacturing facilities in 11 countries. Zoetis filed with U.S. regulators for an IPO of Class A common stock August 2012 and completion was set for January 2013. Pfiser spun off Zoetis as part of its strategic plan to shed entities outside its core medicine business.
No comments:
Post a Comment